By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Drugs in Development Information for BIIB021
Email this page to a colleague
What is the development status for investigational drug BIIB021?
BIIB021 is an investigational drug.
There have been 7 clinical trials for BIIB021.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Breast Neoplasms, Leukemia, and Gastrointestinal Stromal Tumors. The leading clinical trial sponsors are Biogen and [disabled in preview].
Summary for BIIB021
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,004 |
| WIPO Patent Applications | 686 |
| Japanese Patent Applications | 462 |
| Clinical Trial Progress | Phase 2 (2009-11-01) |
| Vendors | 84 |
Recent Clinical Trials for BIIB021
| Title | Sponsor | Phase |
|---|---|---|
| Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding | Biogen | Phase 2 |
| Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors | Biogen | Phase 1 |
| An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) | Biogen | Phase 2 |
Clinical Trial Summary for BIIB021
Top disease conditions for BIIB021
Top clinical trial sponsors for BIIB021
US Patents for BIIB021
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
